WSL
MACK

Western Standard LLC’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Western Standard LLC’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,172,513
Closed -$32.1M – 31
2024
Q1 		$32.1M Hold
2,172,513
– – 15.37% 2
2023
Q4 		$29.1M Buy
2,172,513
+278,500
+15% +$3.52M 19.4% 2
2023
Q3 		$23.4M Buy
1,894,013
+221,550
+13% +$2.68M 21.09% 1
2023
Q2 		$20.6M Hold
1,672,463
– – 17.72% 1
2023
Q1 		$20.6M Buy
1,672,463
+142,969
+9% +$1.68M 20.85% 1
2022
Q4 		$17.5M Buy
1,529,494
+357,031
+30% +$2.94M 15.43% 1
2022
Q3 		$4.4M Sell
1,172,463
-97,095
-8% -$448K 5.03% 8
2022
Q2 		$7.55M Buy
1,269,558
+97,095
+8% +$548K 5.73% 4
2022
Q1 		$6.8M Hold
1,172,463
– – 6.46% 5
2021
Q4 		$4.58M Sell
1,172,463
-97,095
-8% -$421K 2.71% 11
2021
Q3 		$6.13M Hold
1,269,558
– – 3.49% 7
2021
Q2 		$8.11M Buy
1,269,558
+257,987
+26% +$1.7M 4.77% 5
2021
Q1 		$6.35M Hold
1,011,571
– – 4.53% 5
2020
Q4 		$6.97M Sell
1,011,571
-51,696
-5% -$255K 7.97% 1
2020
Q3 		$4.25M Buy
1,063,267
+193,913
+22% +$712K 4.83% 8
2020
Q2 		$2.9M Buy
869,354
+26,441
+3% +$90.2K 3.47% 12
2020
Q1 		$1.81M Hold
842,913
– – 1.67% 19
2019
Q4 		$2.65M Hold
842,913
– – 2.07% 17
2019
Q3 		$3.79M Buy
842,913
+48,848
+6% +$244K 3% 12
2019
Q2 		$3.78M Buy
794,065
+253,434
+47% +$1.2M 2.79% 13
2019
Q1 		$2.96M Buy
540,631
+349,520
+183% +$1.61M 2.62% 11
2018
Q4 		$580K Buy
+191,111
New +$663K 0.54% 35

Other funds holding MACK

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
RA
Rise Advisors Rochester, New York $355M AUM 20.51% 1-Year Est. Return
JC
JBF Capital Aspen, Colorado $764M AUM 24.26% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Western Standard LLC's MACK Position: Q2 2024 in Review

Western Standard LLC sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q2 2024, closing a stake of 2,172,513 shares — an estimated $32.1M sold.

Western Standard LLC first reported a position in MACK in Q4 2018 and held it in 22 quarters. The position peaked at $32.1M in Q1 2024. 12 funds tracked by Wall St. Rank hold MACK as of Q2 2024.

  • Western Standard LLC reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
  • Western Standard LLC sold 2,172,513 Merrimack Pharmaceuticals, Inc. shares in Q2 2024, an estimated $32.1M.
  • Western Standard LLC first reported a position in Merrimack Pharmaceuticals, Inc. in Q4 2018 and held it in 22 quarters.
  • Western Standard LLC's Merrimack Pharmaceuticals, Inc. position peaked at $32.1M in Q1 2024.
  • 12 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q2 2024.

Based on Western Standard LLC's 13F filing for Q2 2024, filed 14 Aug 2024.